The EU's CHMP has recommended restricting the use of modafinil-containing medicines to the treatment of sleepiness associated with narcolepsy because of concerns over safety that are already largely reflected in product labelling - including neuropsychiatric disorders and skin and subcutaneous tissue reactions - which it said did not outweigh its benefits in other approved indications.
Medicines containing modafinil, a wakefulness promoting agent that is thought to interact with neurotransmitters in the brain such as dopamine...